AARDVARK THERAPEUTICS, INC. COMMON STOCK
NASDAQ: AARD (Aardvark Therapeutics, Inc.)
Kemas kini terakhir: 2 jam lalu5.27
-0.08 (-1.50%)
| Penutupan Terdahulu | 5.35 |
| Jumlah Dagangan | 28,120 |
| Harga / Buku (P/B) | 1.63 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.28 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.48% |
| Nisbah Semasa (MRQ) | 25.86 |
| Aliran Tunai Operasi (OCF TTM) | -27.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.67 M |
| Pulangan Atas Aset (ROA TTM) | -15.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Aardvark Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -1.17 |
|
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 14.22% |
| % Dimiliki oleh Institusi | 49.49% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |